16 results about "Immune modulator" patented technology

The present disclosure provides a compound of Formula (I), its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof and a method of preparation of the same. In addition, the present disclosure provides a pharmaceutical composition comprising the compound of Formula (I) and its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions. Further, the present disclosure provides a method for prevention or treatment of neurodegenerative disease or for treatment of a condition mediated by aggregation of tau, by administering an effective amount of the compound of Formula (I), its stereoisomers, intermediates, pharmaceutically acceptable salt thereof, or the pharmaceutical composition; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions or with a clinically relevant immune modulator agent.

The invention discloses a lotus-derived polysaccharide targeted nano drug delivery system and application thereof. The lotus-derived polysaccharide targeted nano drug delivery system is composed of an active component and a carrier material wrapping the active component, the active ingredient is lotus root polysaccharide LSP-1, the LSP-1 is homogeneous polysaccharide extracted and purified from lotus roots, the molecular weight is 3.2 * 10 Da, and monosaccharide of the LSP-1 is composed of glucose, galactose and arabinose in a molar ratio of 5.2: 2.8: 1.0; the carrier material is an amphiphilic polymer, poly-beta-amino ester is taken as a main chain, a disulfide bond is introduced into the main chain, and the tail end of the polymer is modified with cell-penetrating peptide TAT and polyethylene glycol; the invention puts forward and verifies a new convergent collaborative immune regulation mechanism for the first time. The observed convergent synergistic effect is specific to the combination of the LSP-1 and the PBAE-based response type carrier, specific biochemical signal channel interaction exists between the LSP-1 and the PBAE-based response type carrier in mechanism, and the convergent synergistic effect can not be achieved through simple superposition of any immunomodulator and any nano-carrier.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.

This present invention relates to small molecules which are biphenyl pyridine rigid compounds with polycyclic heterocycles therapeutically useful as immune modulators These compounds disrupt the PD-1 / PD-L1 checkpoint pathway and may also disrupt one or more related checkpoint pathways. These compounds are useful in treating, preventing or ameliorating disorders such as cancer or infections.

A combination, composition, and method of use of (i) a conjugate comprising a targeted immune modulator and (ii) one or more immune checkpoint inhibitors for reprogramming M2-like macrophages into M1-like macrophages to reverse the pro-inflammatory response observed in cancer into an anti-inflammatory response. In at least one embodiment of a method of treating a subject having cancer, the subject is experiencing or at risk of experiencing cancer or cancer recurrence, and the step of administering a first treatment further comprises administering or applying to the subject a therapeutically effective amount of at least one compound or a pharmaceutically acceptable salt or hydrate thereof.

The present invention provides novel compositions and methods for inducing and / or activating regulatory T cells (Treg). Wherein a method of treating, inhibiting, and / or preventing a disease or disorder in a subject in need thereof, said method comprising administering at least two immune modulators to said subject, is disclosed.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.

The present disclosure provides a method of enhancing an immune response in a subject in need thereof, including administering an effective amount of an antigen with an immune modulator to the subject, wherein the immune modulator is a quaternary immunomodulatory nanoparticle (QIN). The present disclosure also provides the use of the QIN in the manufacture of a chimeric nanoparticle, a pharmaceutical composition and a medicament for treating a subject suffering from a cancer or virus infection.

This invention provides combinations of kynurenine and antigen presenting cells (APC) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of Type 1 Diabetes (TID)) or alopecia areata (AA). Uses of kynurenine and antigen presenting cells (APC) as an immune modulator for the treatment of TID or AA are also provided.

The invention discloses antisense oligonucleotide of a coding gene of targeted apoptosis inhibition protein BIRC6, and the antisense oligonucleotide and a nano-material carrier loaded with the antisense oligonucleotide can reduce expression ability of the BIRC6 gene in hematopoietic stem cells in a targeted manner, inhibit survival advantages of senescence hematopoietic stem cells and medullary system biased differentiation, reverse senescence of the hematopoietic stem cells, and inhibit apoptosis of the hematopoietic stem cells. The invention also discloses application of the antisense oligonucleotide and the nano-material carrier loaded with the antisense oligonucleotide in preparation of anti-aging drugs, drugs for promoting hematopoietic reconstitution after transplantation and immunomodulator drugs, and also discloses application of the antisense oligonucleotide and the nano-material carrier loaded with the antisense oligonucleotide in preparation of anti-aging drugs, drugs for promoting hematopoietic reconstitution after transplantation and immunomodulator drugs.

Synthetic oligosaccharides and mixtures thereof which resemble polysaccharides produced by plants, yeast and other fungi, bacteria, and algae are described. The oligosaccharides and compositions provided herein are useful as synbiotics, prebiotics, immune modulators, digestion aids, and food additives.

The present invention relates to an attenuated oncolytic virus including a recombinant polynucleotide, where the recombinant polynucleotide includes a 5'UTR, an internal ribosomal entry site (IRES), an encoding region, at least one protease cleavage site, and a 3' UTR, where the encoding region encodes an immune modulator polypeptide and uses of the attenuated oncolytic virus.

Antibodies, particularly humanized and variant antibodies and fragments thereof, which bind to TGF-β1 are provided, recognizing human and mouse TGF-β1, particularly that preferentially bind TGF-β1, including which do not recognize or bind TGF-β2 or TGF-β3. Humanized and variant antibodies provided are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and / or combination with chemotherapeutics, immune modulators, or anti-cancer agents and / or with other antibodies or fragments thereof. Particular antibodies are exemplified herein, including antibodies 13A1-2A, 13A1-2B, 13A1-2C, 13A1-2D, 13A1-2E, 13A1-2F, 13A1-2G, 13A1-2H, 13A1-2I, 13A1-2J, 13A1-AF, 13A1-AG, 13A1-AH, 13A1-BF, 13A1-BG, 13A1-BH, 13A1-CF, 13A1-CG, 13A1-CH, 13A1-DF, 13A1-DG, 13A1-DH, 13A1-EF, 13A1-EG and 13A1-EH.

Provided herein are compositions, systems, methods, and kits related to chemical immunology for use in assessing and monitoring disease stages and phases, predicting the likelihood of disease progression, predicting and monitoring responses to disease therapies, and treating disease conditions.

The present invention relates to the efficient delivery of anti-infective activity, immune modulators, or growth-promoting biomolecules directly to the gastrointestinal tract of animals via a biodelivery platform.SOLUTION: The biodelivery platform can be a genetically modified microorganism. Delivery can be achieved using Lactobacillus species fix in the gastrointestinal tract. The anti-infective activity can be a bactericidal or bacteriostatic peptide, an antibody or fragment thereof that specifically recognizes a pathogen, or a phage or lytic peptide derived from a phage that specifically targets a particular pathogen.SELECTED DRAWING: None

This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.